Uncategorized
SpaceX Could Swing $128 Billion After Earnings
calendar_month Oct 19, 2026, BY Kaustubh Bagalkote
Uncategorized
‘CoreWeave Is the Canary in the Coal Mine’: Expert Warns More AI Debt Will Slide into Distress
calendar_month Oct 19, 2026, BY Erica Kollmann
DXC Technology Eyes $2.4 Billion Insurance Unit Sale to Eldridge

DXC Technology Company (NYSE:DXC) stock is trading higher Monday following reports that the company is in advanced talks to sell its insurance software business to private investment firm Eldridge Industries for $2.4 billion. Reuters reported Monday, citing people familiar with…

Uncategorized , calendar_month Oct 19, 2026
Xanadu Stock Tumbles: What’s Going On?

Xanadu Quantum Technologies Ltd. (TSX:XNDU) shares are sliding Monday after an early pop, despite news of provisional DARPA funding. Here’s what you should know. Xanadu Quantum stock is testing key support levels. Why are XNDU shares at support? Xanadu Pulls…

Uncategorized, calendar_month Oct 19, 2026
Homebuilder Sentiment Hits 2012 Lows As Stocks Trade Like They Did During COVID-19 Pandemic

In April 2020, with most of America locked indoors, the country’s home builders recorded their darkest mood in eight years. Six years later, with no virus and no lockdown, they feel even worse. The NAHB/Wells Fargo Housing Market Index (HMI),…

Uncategorized, calendar_month Oct 19, 2026
FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated

The U.S. Food and Drug Administration (FDA) on Monday granted accelerated approval to GSK plc (NYSE:GSK) for Jemperli (dostarlimab-gxly), making it the first and only immunotherapy for adults with stage II and III mismatch repair deficient (dMMR) or microsatellite instability-high…

Uncategorized, calendar_month Oct 19, 2026
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success

Gilead Sciences Inc. (NASDAQ:GILD) on Monday announced 12-week induction data from its Phase 2 SWIFT trial evaluating emvistegrast, an investigational once-daily oral treatment for adults with moderately to severely active ulcerative colitis. The biopharmaceutical company revealed the late-breaking findings on…